Natera (NTRA) stock: Winston Score and insider trades

Natera is a genetic testing company that analyzes DNA to help doctors make better medical decisions. Its main products include Panorama, a prenatal test that checks unborn babies for chromosomal conditions, and Signatera, a test that detects tiny amounts of cancer DNA in a patient's blood to track whether cancer is returning. Its customers are primarily physicians, hospitals, and patients across the prenatal, oncology, and organ transplant markets. Natera makes money by charging for each test it processes, with payment coming from insurance companies, government health programs like Medicare, and patients directly. The company operates mainly in the United States but is expanding internationally. Its competitive moat comes from proprietary testing technology and a large database of genetic information that improves test accuracy over time. Despite strong revenue growth and a 65% gross margin, Natera is still unprofitable, and its key challenge is converting that growth into consistent operating profits while competing against larger diagnostics companies.

Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-17.